Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1 IPO registration
- 4.5 Description of Securities
- 5.1 Opinion of Goodwin Procter LLP As to the Validity of the Securities Being Registered
- 10.20 Registration Rights Agreement, Dated As of September 26, 2024, by and Between CERO Therapeutics Holdings, Inc. and the Investors Party Thereto
- 10.21 Consent and Waiver Agreement, Dated As of September 26, 2024, by and Between CERO Therapeutics Holdings, Inc. and the Investors Party Thereto
- 23.1 Consent of Citrin Cooperman & Company LLP (with Respect to the Phoenix Biotech Acquisition Corp. Financial Statements)
- 23.2 Consent of Wolf & Company, P.C. (with Respect to CERO Therapeutics, Inc. Financial Statements)
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
Associated filings
- 23 Jan 25 424B3 Prospectus supplement
- 14 Jan 25 424B3 Prospectus supplement
- 7 Jan 25 424B3 Prospectus supplement
- 6 Dec 24 EFFECT Notice of effectiveness
- 5 Dec 24 424B3 Prospectus supplement
- 25 Nov 24 S-1/A IPO registration (amended)
- 22 Oct 24 S-1/A IPO registration (amended)
-
21 Oct 24 S-1 IPO registration
CERO similar filings
Filing view
External links